Literature DB >> 34588364

Relationship between Selective IgA Deficiency and COVID-19 Prognosis.

Fatih Çölkesen1, Bahar Kandemir2, Şevket Arslan1, Fatma Çölkesen3, Eray Yıldız1, Celalettin Korkmaz4, Hülya Vatansev4, Recep Evcen1, Filiz Sadi Aykan1, Mehmet Kılınç1, Gökhan Aytekin5, Bahadır Feyzioğlu6, Metin Doğan7, Turgut Teke4.   

Abstract

The prevalence and mortality rates of coronavirus disease 2019 (COVID-19) widely vary among populations. Mucosal immunity is the first barrier to the pathogen's entry into the body. Immunoglobulin A (IgA) is the primary antibody responsible for mucosal immunity. We explored the relationship between selective IgA deficiency (SIgAD) and COVID-19 severity. We included 424 patients (203 women) with COVID-19. Eleven patients had SIgAD. Laboratory data of patients with SIgAD and normal IgA levels were compared. The relationship between SIgAD and severe COVID-19 infection was explored using logistic regression analysis. In the univariate logistic regression analysis, the risk of severe COVID-19 disease in patients with SIgAD was approximately 7.7-fold higher than that in other patients (odds ratio [OR], 7.789; 95% confidence interval [CI], 1.665-36.690, P = 0.008), while it was 4-fold (OR, 4.053; 95% CI, 1.182-13.903, P = 0.026) higher in the multivariate logistic regression analysis. Serum IgA levels were positively correlated with total lymphocyte counts and negatively correlated with C-reactive protein levels, which was a risk factor for severe COVID-19. In patients with SIgAD, the number of severe acute respiratory coronaviruses 2 that pass through mucosal membranes may be increased, leading to complications such as cytokine storm syndrome and acute respiratory distress syndrome.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; mucosal immunity; selective IgA deficiency

Mesh:

Substances:

Year:  2021        PMID: 34588364     DOI: 10.7883/yoken.JJID.2021.281

Source DB:  PubMed          Journal:  Jpn J Infect Dis        ISSN: 1344-6304            Impact factor:   1.362


  3 in total

1.  SARS-CoV-2-neutralizing humoral IgA response occurs earlier but modest and diminishes faster compared to IgG response.

Authors:  Yuki Takamatsu; Kazumi Omata; Yosuke Shimizu; Noriko Kinoshita-Iwamoto; Mari Terada; Tetsuya Suzuki; Shinichiro Morioka; Yukari Uemura; Norio Ohmagari; Kenji Maeda; Hiroaki Mitsuya
Journal:  bioRxiv       Date:  2022-06-09

2.  Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern.

Authors:  Eliott Lafon; Michael Jäger; Angelika Bauer; Markus Reindl; Rosa Bellmann-Weiler; Doris Wilflingseder; Cornelia Lass-Flörl; Wilfried Posch
Journal:  J Allergy Clin Immunol       Date:  2022-01-29       Impact factor: 14.290

Review 3.  Nature of Acquired Immune Responses, Epitope Specificity and Resultant Protection from SARS-CoV-2.

Authors:  Reginald M Gorczynski; Robyn A Lindley; Edward J Steele; Nalin Chandra Wickramasinghe
Journal:  J Pers Med       Date:  2021-11-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.